论文部分内容阅读
目的观察和比较莫西沙星与左氧氟沙星在治疗耐药性肺结核中的临床疗效。方法 76例耐药性肺结核患者随机分为两组,观察组(莫西沙星组)在基础抗结核药物治疗上加用莫西沙星,对照组(左氧氟沙星组)在基础抗结核药物治疗上加用左氧氟沙星。观察和比较两组临床疗效及不同时期痰菌转阴情况、X线变化情况、不良反应。结果莫西沙星组治疗总有效率(85%)明显高于左氧氟沙星组(61.1%)(P<0.05)。结论莫西沙星治疗耐药肺结核疗效显著,可提高耐药性肺结核患者的治疗,在临床中可以推广应用。
Objective To observe and compare the clinical efficacy of moxifloxacin and levofloxacin in the treatment of drug resistant pulmonary tuberculosis. Methods A total of 76 patients with drug-resistant pulmonary tuberculosis were randomly divided into two groups. The observation group (moxifloxacin group) was treated with moxifloxacin on the basis of anti-tuberculosis drugs and the control group (levofloxacin group) on the basis of anti-tuberculosis drugs Levofloxacin. To observe and compare the clinical curative effect of the two groups and the different stages of sputum bacteria negative conversion, X-ray changes, adverse reactions. Results The total effective rate (85%) of moxifloxacin group was significantly higher than that of levofloxacin group (61.1%) (P <0.05). Conclusion The efficacy of moxifloxacin in the treatment of drug-resistant pulmonary tuberculosis is significant, which can improve the treatment of patients with drug-resistant tuberculosis and can be widely applied in clinic.